Abstract: The invention relates to the utilization of specific cell surface biomarkers (preferably cell specific receptors) to generate a reversible layer-by-layer scaffold for the functionalization of cells. The cells of the present invention can be used in a wide variety of distinct applications, including cellular targeting, imaging, drug delivery, purification, cell sensing, diagnosis and waste stream/body fluid purification.

Abstract: The present invention relates to the use of sulfocysteine and derivatives thereof to increase the gluthathione pool in cells.

Abstract: Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can also comprise performing an assay to determine if contacting the at least one collagen-containing tissue matrix with a proteolytic enzyme has altered the at least one collagen-containing tissue matrix to reduce a human immune response to the tissue matrix.

Abstract: Early vascular cells (EVCs), including endothelial cells and pericytes, are generated from hiPSCs. Unlike the isolated endothelial progenitor cells, the differentiated ECs mature and are functional. When encapsulated in synthetic hydrogel, EVCs respond to matrix cues and self-assembled to form three-dimensional EVCs. Moreover, these EVCs respond to hypoxic microenvironment and undergo vasculogenesis to form complex 3D networks.

Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.

Abstract: The present invention relates to a method for inducing differentiation myeloid-derived suppressor cells from cord blood CD34 positive cells and proliferating the same, and a use of the myeloid-derived suppressor cells. More specifically, myeloid-derived suppressor cells are induced to differentiate and proliferated by culturing cord blood CD34 positive cells in the presence of a cytokine cocktail of GM-CSF and SCF, such that myeloid-derived suppressor cells can be mass-produced in vitro, and the myeloid-derived suppressor cells can be used in preventing or treating immunorejection-related diseases such as graft-versus-host disease.

Abstract: Provided is a method for isolating and proliferating autologous cancer antigen-specific CD8+ T cells, and more particularly, a method for selecting an epitope recognized by CD8+ T cells from autologous cancer antigens present in blood of individual cancer patients; and isolating autologous cancer antigen-specific CD8+ T cells by using a peptide of the selected epitope, and a method of massively proliferating CD8+ T cells by using the method. According to the present invention, it is possible to isolate autologous cancer antigen-specific CD8+ T cells by using the peptide of the CD8 T cell epitope of the autologous cancer antigen present in blood of individual cancer patients instead of a heterologous antigen. Therefore, by using T cells recognizing the autologous cancer antigen, it is possible to effectively select and eliminate cancer cells derived from the cancer patient's own cells. Thus, T cells can be applied to treatment and alleviation of cancer diseases without side effects.

Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

Abstract: The invention relates to a method of producing CD34+CD4dim megakaryocyte (MK) progenitor cells, and substantially pure cell population of megakaryocyte precursor cells obtained by said method. The invention also relates to a method of producing proplatelet-bearing MKs and/or platelets using the CD34+CD4dim cells.

Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract: The present invention concerns a method of producing brown/beige adipocytes from white adipose tissue cells and/or mesenchymal stem cells, in particular from subcutaneous white adipose tissue cells, and the use of said brown/beige adipocytes in a cell based therapy of a subject or in screening platforms.

Abstract: The present invention relates to a cell culture medium, in particular for culturing autologous fibroblasts, for use in aesthetic medicine for skin transplantation, said culture medium being serum-free and being characterized in that it contains glucose in a much lower quantity than conventional culture media.

Abstract: Disclosed herein are compositions and methods involving stem cells biopreserved on microcarriers, which can be thawed and expanded, all while maintaining their key attributes, such as their proliferative capacity, identity, functionality, and potency. Disclosed is a method for generating microcarriers-seeded-stem cells, as well as a post biopreservation procedure for thawing and inoculating bioreactors to achieve a rapid and scalable stem cells expansion.

Abstract: The invention relates to immuno-oncology mesodermal progenitor (ioMP) cells and their use in therapy.

Abstract: The technology described herein is directed to methods and devices that can be used to induce functional organ structures to form within an implantation device by implanting it in vivo within the body of a living animal, and allowing cells and tissues to impregnate the implantation device and establish normal microenvironmental architecture and tissue-tissue interfaces. Then the contained cells and tissues can be surgically removed intact and either transplanted into another animal or maintained ex vivo by perfusing it through one or more of the fluid channels with medium and/or gases necessary for cell survival.

Abstract: Provided is a composite binder material, a cell aggregate, a cell accumulation method, a cell preservation method, and a method of manufacturing a composite binder that can supply oxygen and nutrients to cells. A composite binder material comprises a binder material and a cell non-adhesive portion. A binder material formed in a membrane shape is provided between a first cell sheet and a second cell sheet. The cell non-adhesive portion formed at least in a portion of one membrane surface and/or other membrane surface of the binder material. A plurality of pores are formed in the binder material, and the pores open to the one membrane surface coming into contact with one sheet surface of the first cell sheet. The pores penetrate in a thickness direction and a surface direction along the one membrane surface. The porosity of the binder material is set to be at least 50%.

Abstract: Compositions and methods of producing mammalian cell populations that include a high proportion of pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes. Also provided are materials and methods for the direct differentiation of stem cells, such as embryonic stem cells, into functional pancreatic beta cells. The disclosure provides the benefit of direct differentiation, which results in the production of functional pancreatic beta cells efficiently and at low cost.

Abstract: The present invention relates to compositions and methods for generating populations of tissue precursor cells from pluripotent cells, and preferably induction of stem cells into definitive endoderm to generate anterior foregut endoderm from pluripotent cells. The anterior foregut endoderm cells can then be differentiated into an alveolar epithelial type II cell.

Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.

Abstract: The disclosure provides methods and compositions useful for obtaining induced stem cells, methods of making and use thereof.

Abstract: The present document is directed to a new poxvirus infecting salmon. The present document further discloses the genomic sequence of this double-stranded DNA virus and the use of this sequence information for detection, diagnosis and/or vaccine development for the virus.

Abstract: There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.

Abstract: Attenuated isolates of the Arkansas serotype of infectious bronchitis virus (IBV), including the IBV isolate ArkGA p60 deposited at the ATCC under Patent Designation PTA-123783, and compositions thereof are presented. Methods for administering the isolates or compositions as vaccines to the prevent virulent IBV infection in birds of the order Galliformes also presented.

Abstract: The invention generally relates to engineered prephenate dehydrogenases and arogenate dehydrogenases and methods of using the same. More specifically, the invention relates in part to compositions including engineered prephenate dehydrogenases (PDH) polypeptides and engineered arogenate dehydrogenase (ADH) polypeptides with altered substrate preferences and tyrosine sensitivities and methods of using the same.

Abstract: Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B3 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.

Abstract: The invention relates to a cellobiose phosphorylase, which catalyzes, among other things, the synthesis of cellobiose from glucose 1-phosphate and glucose. The cellobiose phosphorylase according to the invention can be understood as a mutation of the cellobiose phosphorylase from Cellulomonas uda. In comparison to cellobiose phosphorylase of the wild type, the cellobiose phosphorylase according to the invention is distinguished by improved activity and process stability, in particular temperature stability, and lower product inhibition and therefore is especially suitable for use in industrial processes.

Abstract: This disclosure provides various TcBuster transposases and transposons, systems, and methods of use.

Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.

Abstract: The present invention relates to isolated polypeptides having beta-xylosidase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The present disclosure provides LG12-clade enzyme variants, compositions comprising these enzyme variants, and method of using these enzymes and compositions, as well as the polynucleotides encoding these enzymes, the vectors comprising these polynucleotides, and the host cells transformed with such vectors.

Abstract: Herein is reported a polypeptide comprising the amino acid sequence of SEQ ID NO: 38 as sole Listeria monocytogenes derived polypeptide and its use in conjugating polypeptides.

Abstract: The present invention provides serine protease variants produced there from. Specifically, the present invention provides serine protease variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants.

Abstract: The present invention pertains to fusion constructs of dimeric proteins, wherein the portions of the protein are fused to either to the CH1 domain of the CL domain of an antibody. These fusion constructs improve stability, solubility, circulation half-life and production yield of the dimeric protein.

Abstract: The disclosure provides compositions and methods for counteracting the effects of direct activated Factor XI (FXIa) inhibitors in a subject by administering a variant of FXIa.

Abstract: Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.

Abstract: Genetically engineered cells and methods are presented that allow for the production of various value products from CO2. Contemplated cells have a CBB cycle that is genetically modified such that two molecules of CO2 fixed in the CBB cycle can be withdrawn from the modified CBB cycle as a single C2 compound. In contemplated aspects a CBB cycle includes an enzymatic activity that generates the single C2 compound from a compound of the CBB cycle, while further modifications to the CBB cycle will not introduce additional recombinant enzymatic activity/activities outside the already existing catalytic activities in the CBB cycle.

Abstract: A system for continuous mutagenesis to facilitate directed evolution, the system including DNA polymerases carrying the novel K54E point mutation, and other point mutations including I709N, A759R, D424A (herein called K54E_LF Pol I) and this methods of use to produce and detect lines where mutagenesis is continuous and does not exhibit the usual decline in mutagenesis with sequential cloning.

Abstract: This disclosure provides, among other things, a composition comprising: a 5? exonuclease; a strand-displacing polymerase; and optionally a single strand DNA binding protein and/or a ligase. A method for polynucleotide assembly to form a synthon, as well as a kit for performing the same, are also described.

Abstract: The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest.

Abstract: The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest.

Abstract: The present disclosure provides a HTP microbial genomic engineering platform that is computationally driven and integrates molecular biology, automation, and advanced machine learning protocols. This integrative platform utilizes a suite of HTP molecular tool sets to create HTP genetic design libraries, which are derived from, inter alia, scientific insight and iterative pattern recognition. The HTP genomic engineering platform described herein is microbial strain host agnostic and therefore can be implemented across taxa. Furthermore, the disclosed platform can be implemented to modulate or improve any microbial host parameter of interest.

Abstract: Methods for construction of DNA origami nanostructures, as well as for binding, isolation, linking, and deep sequencing information, such as both of TCR alpha and beta CDR3 mRNA, from individual cells within a mixed population of cells without the need for single cell sorting (FIG. 1).

Abstract: High-fidelity, high-throughput nucleic acid sequencing enables healthcare practitioners and patients to gain insight into genetic variants and potential health risks. However, previous methods of nucleic acid sequencing often introduces sequencing errors (for example, mutations that arise during the preparation of a nucleic acid library, during amplification, or sequencing). Provided herein are methods and compositions for sequencing nucleic acids. Further provided are methods of identifying an error in a nucleic acid sequence.

Abstract: Provided are compositions related to HSD17B13 variants, including isolated nucleic acids and proteins related to variants of HSD17B13, and cells comprising those nucleic acids and proteins. Also provided are methods related to HSD17B13 variants. Such methods include methods for modifying a cell through use of any combination of nuclease agents, exogenous donor sequences, transcriptional activators, transcriptional repressors, and expression vectors for expressing a recombinant HSD17B13 gene or a nucleic acid encoding an HSD17B13 protein. Also provided are therapeutic and prophylactic methods for treating a subject having or at risk of developing chronic liver disease.

Abstract: Disclosed are double stranded RNA molecules that are toxic to coleopteran insects. In particular, interfering RNA molecules that capable of interfering with pest histone genes and that are toxic to the target pest are provided. Further, methods of making and using the interfering RNA, for example in transgenic plants to confer protection from insect damage are disclosed.

Abstract: Antisense oligonucleotides capable of preventing or reducing exon 73 inclusion into the human COL7A mRNA are characterized in various ways: (a) the oligonucleotide's sequence includes at most two CpG sequences; (b) the oligonucleotide has a length of no more than 24 nucleotides; (c) the oligonucleotide is capable of annealing to the (SRp40/SC35 binding/ESE) element in exon73. These oligonucleotides can usefully be oligoribonucleotides with modified internucleosidic linkages e.g. phosphorothioate linkages.

Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved up-take. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.

Abstract: Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.

Abstract: The present invention is directed to anti-sense microRNA-328 in a form of oligodeoxyribonucleotides, or locked nucleic acid (LNA)-modified, and phosphorothioated (PS) bond-modified oligonucleotides. The present invention is also directed to a pharmaceutical composition comprising the anti-sense microRNA-328 composition and a pharmaceutically acceptable carrier. The present invention is further directed to a method for preventing or treating myopia by administering to a subject the anti-sense microRNA-328 composition. A preferred route of administration is topical administration to the eyes.